Cargando…
Serum Malondialdehyde as a Biomarker of Oxidative Stress in Patients with Primary Ocular Carcinoma: Impact on Response to Chemotherapy
PURPOSE: To study the level of serum malondialdehyde (MDA), a biomarker of oxidative stress before and after chemotherapy in various ocular malignancies and to correlate its significance with clinicopathological parameters. METHODS: Thirty two histopathologically confirmed cases of primary ocular ma...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924123/ https://www.ncbi.nlm.nih.gov/pubmed/33664564 http://dx.doi.org/10.2147/OPTH.S287747 |
_version_ | 1783659026275368960 |
---|---|
author | Maurya, Rajendra Prakash Prajapat, Manish Kumar Singh, Virendra Pratap Roy, Meghna Todi, Ravina Bosak, Sanjay Singh, Sunit Kumar Chaudhary, Sunil Kumar, Anil Morekar, Sunil R |
author_facet | Maurya, Rajendra Prakash Prajapat, Manish Kumar Singh, Virendra Pratap Roy, Meghna Todi, Ravina Bosak, Sanjay Singh, Sunit Kumar Chaudhary, Sunil Kumar, Anil Morekar, Sunil R |
author_sort | Maurya, Rajendra Prakash |
collection | PubMed |
description | PURPOSE: To study the level of serum malondialdehyde (MDA), a biomarker of oxidative stress before and after chemotherapy in various ocular malignancies and to correlate its significance with clinicopathological parameters. METHODS: Thirty two histopathologically confirmed cases of primary ocular malignancies were included in this longitudinal cohort study. Detailed clinicopathological assessment was done. Analysis of serum MDA level in the patient before and after chemotherapy was measured and its prognostic significance was analyzed. RESULTS: Maximum cases were of eyelid malignancy (n=18, 56.2%) followed by retinoblastoma (18.8%) and OSSN (6, 18.8%). About 43.75% patients were in the advanced-stage. The tumor was histopathologically well-differentiated in 20 (62.5%) cases. Most common malignancy was sebaceous gland carcinoma of the eyelid (n=10,31.25%). Serum MDA level in patients were significantly higher than controls [5.5712±0.32779 vs 2.5531±0.08056 nmol/mL, p<0.001]. Level was significantly reduced after chemotherapy (4.5146±0.23209 nmol/mL). Serum MDA was maximum in cases of rhabdomyosarcoma (5.9450±0.23335 nmol/mL) and retinoblastoma (5.7433±0.14334 nmol/mL). It was minimum in basal cell carcinoma (5.3775±0.17746 nmol/mL). Pre chemotherapy serum MDA level was significantly higher in patients having larger tumor (>20mm, p< 0.001) and having lymph node metastasis than those without lymph node metastasis [5.8350±0.17113 vs 5.4833± 0.32193 nmol/mL, p<0.006]. No significant difference was observed in post chemotherapy serum MDA level as for as size of tumor (p=0.947) and histopathological differentiation (p=0.109) was concerned. CONCLUSION: The serum MDA level is a potential biomarker in primary ocular carcinoma to assess oxidative stress and its impact on response to chemotherapy. |
format | Online Article Text |
id | pubmed-7924123 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-79241232021-03-03 Serum Malondialdehyde as a Biomarker of Oxidative Stress in Patients with Primary Ocular Carcinoma: Impact on Response to Chemotherapy Maurya, Rajendra Prakash Prajapat, Manish Kumar Singh, Virendra Pratap Roy, Meghna Todi, Ravina Bosak, Sanjay Singh, Sunit Kumar Chaudhary, Sunil Kumar, Anil Morekar, Sunil R Clin Ophthalmol Original Research PURPOSE: To study the level of serum malondialdehyde (MDA), a biomarker of oxidative stress before and after chemotherapy in various ocular malignancies and to correlate its significance with clinicopathological parameters. METHODS: Thirty two histopathologically confirmed cases of primary ocular malignancies were included in this longitudinal cohort study. Detailed clinicopathological assessment was done. Analysis of serum MDA level in the patient before and after chemotherapy was measured and its prognostic significance was analyzed. RESULTS: Maximum cases were of eyelid malignancy (n=18, 56.2%) followed by retinoblastoma (18.8%) and OSSN (6, 18.8%). About 43.75% patients were in the advanced-stage. The tumor was histopathologically well-differentiated in 20 (62.5%) cases. Most common malignancy was sebaceous gland carcinoma of the eyelid (n=10,31.25%). Serum MDA level in patients were significantly higher than controls [5.5712±0.32779 vs 2.5531±0.08056 nmol/mL, p<0.001]. Level was significantly reduced after chemotherapy (4.5146±0.23209 nmol/mL). Serum MDA was maximum in cases of rhabdomyosarcoma (5.9450±0.23335 nmol/mL) and retinoblastoma (5.7433±0.14334 nmol/mL). It was minimum in basal cell carcinoma (5.3775±0.17746 nmol/mL). Pre chemotherapy serum MDA level was significantly higher in patients having larger tumor (>20mm, p< 0.001) and having lymph node metastasis than those without lymph node metastasis [5.8350±0.17113 vs 5.4833± 0.32193 nmol/mL, p<0.006]. No significant difference was observed in post chemotherapy serum MDA level as for as size of tumor (p=0.947) and histopathological differentiation (p=0.109) was concerned. CONCLUSION: The serum MDA level is a potential biomarker in primary ocular carcinoma to assess oxidative stress and its impact on response to chemotherapy. Dove 2021-02-26 /pmc/articles/PMC7924123/ /pubmed/33664564 http://dx.doi.org/10.2147/OPTH.S287747 Text en © 2021 Maurya et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Maurya, Rajendra Prakash Prajapat, Manish Kumar Singh, Virendra Pratap Roy, Meghna Todi, Ravina Bosak, Sanjay Singh, Sunit Kumar Chaudhary, Sunil Kumar, Anil Morekar, Sunil R Serum Malondialdehyde as a Biomarker of Oxidative Stress in Patients with Primary Ocular Carcinoma: Impact on Response to Chemotherapy |
title | Serum Malondialdehyde as a Biomarker of Oxidative Stress in Patients with Primary Ocular Carcinoma: Impact on Response to Chemotherapy |
title_full | Serum Malondialdehyde as a Biomarker of Oxidative Stress in Patients with Primary Ocular Carcinoma: Impact on Response to Chemotherapy |
title_fullStr | Serum Malondialdehyde as a Biomarker of Oxidative Stress in Patients with Primary Ocular Carcinoma: Impact on Response to Chemotherapy |
title_full_unstemmed | Serum Malondialdehyde as a Biomarker of Oxidative Stress in Patients with Primary Ocular Carcinoma: Impact on Response to Chemotherapy |
title_short | Serum Malondialdehyde as a Biomarker of Oxidative Stress in Patients with Primary Ocular Carcinoma: Impact on Response to Chemotherapy |
title_sort | serum malondialdehyde as a biomarker of oxidative stress in patients with primary ocular carcinoma: impact on response to chemotherapy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924123/ https://www.ncbi.nlm.nih.gov/pubmed/33664564 http://dx.doi.org/10.2147/OPTH.S287747 |
work_keys_str_mv | AT mauryarajendraprakash serummalondialdehydeasabiomarkerofoxidativestressinpatientswithprimaryocularcarcinomaimpactonresponsetochemotherapy AT prajapatmanishkumar serummalondialdehydeasabiomarkerofoxidativestressinpatientswithprimaryocularcarcinomaimpactonresponsetochemotherapy AT singhvirendrapratap serummalondialdehydeasabiomarkerofoxidativestressinpatientswithprimaryocularcarcinomaimpactonresponsetochemotherapy AT roymeghna serummalondialdehydeasabiomarkerofoxidativestressinpatientswithprimaryocularcarcinomaimpactonresponsetochemotherapy AT todiravina serummalondialdehydeasabiomarkerofoxidativestressinpatientswithprimaryocularcarcinomaimpactonresponsetochemotherapy AT bosaksanjay serummalondialdehydeasabiomarkerofoxidativestressinpatientswithprimaryocularcarcinomaimpactonresponsetochemotherapy AT singhsunitkumar serummalondialdehydeasabiomarkerofoxidativestressinpatientswithprimaryocularcarcinomaimpactonresponsetochemotherapy AT chaudharysunil serummalondialdehydeasabiomarkerofoxidativestressinpatientswithprimaryocularcarcinomaimpactonresponsetochemotherapy AT kumaranil serummalondialdehydeasabiomarkerofoxidativestressinpatientswithprimaryocularcarcinomaimpactonresponsetochemotherapy AT morekarsunilr serummalondialdehydeasabiomarkerofoxidativestressinpatientswithprimaryocularcarcinomaimpactonresponsetochemotherapy |